Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group (Journal article)

Fountzilas, G./ Athanassiadis, A./ Kalogera-Fountzila, A./ Aravantinos, G./ Bafaloukos, D./ Briasoulis, E./ Dombros, N./ Ioannidis, I./ Pavlidis, N./ Kosmidis, P./ Skarlos, D.

Full metadata record
DC FieldValueLanguage
dc.contributor.authorFountzilas, G.en
dc.contributor.authorAthanassiadis, A.en
dc.contributor.authorKalogera-Fountzila, A.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorDombros, N.en
dc.contributor.authorIoannidis, I.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorSkarlos, D.en
dc.rightsDefault Licence-
dc.subjectAntineoplastic Agents, Phytogenic/administration & dosageen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectBreast Neoplasms/drug therapyen
dc.subjectCarboplatin/administration & dosageen
dc.subjectDrug Resistance, Neoplasmen
dc.subjectInfusions, Intravenousen
dc.subjectMiddle Ageden
dc.subjectPaclitaxel/administration & dosageen
dc.subjectTreatment Outcomeen
dc.titlePaclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Groupen
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.abstract37 patients with advanced breast cancer resistant to anthracyclines were treated with paclitaxel 200 mg/m2 by 3-h infusion and carboplatin at an area under the curve of 7 mg.min/ml every 4 weeks with G-CSF support. There were 5 (14%, 95% CI 3-25%) complete and 11 (30%, 95% CI 15-45%) partial responders. Median duration of response was 11.5 months (range 5.2-16.8+), median time to progression 8 months (range 0.26-16.8+) and median survival 12 months (range 0.5-19.6+). Grade 3-4 leucopenia (27%), thrombocytopenia (10%) and diarrhoea (5%) were noted. In conclusion, the combination of paclitaxel and carboplatin is active and well tolerated in patients with advanced breast cancer resistant to anthracyclines.en
heal.journalNameEur J Canceren
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Fountzilas-1997-Paclitaxel by 3-h in.pdf348.26 kBAdobe PDFView/Open    Request a copy

 Please use this identifier to cite or link to this item:
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.